Literature DB >> 15672234

A high cell density fermentation strategy to produce recombinant malarial antigen in E. coli.

Syed Shams Yazdani1, Ahmad Rushdi Shakri, Chetan E Chitnis.   

Abstract

A high cell density cultivation method was developed to produce recombinant PvRII, a malaria vaccine candidate, in E. coli for use in vaccine studies. Cells were grown in completely defined media and glucose was fed to achieve a specific growth rate of 0.12 h(-1) until cells reached 55 g dry wt l(-1). Culture was then induced with 1 mM: IPTG and cells were further grown for 4 h to reach 85 g dry wt l(-1) at 0.1 h(-1). Recombinant PvRII was purified from inclusion bodies under denaturing conditions using metal affinity chromatography which yielded 10 mg PvRII g(-1) dry wt. After refolding, PvRII was greater than 98% pure, homogeneous and functionally active in that it specifically bound Duffy positive human red cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15672234     DOI: 10.1007/s10529-004-6040-4

Source DB:  PubMed          Journal:  Biotechnol Lett        ISSN: 0141-5492            Impact factor:   2.461


  5 in total

1.  Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies.

Authors:  Francis B Ntumngia; Jesse Schloegel; Samantha J Barnes; Amy M McHenry; Sanjay Singh; Christopher L King; John H Adams
Journal:  Infect Immun       Date:  2012-01-03       Impact factor: 3.441

2.  Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein.

Authors:  Francis B Ntumngia; John H Adams
Journal:  Clin Vaccine Immunol       Date:  2011-11-23

3.  Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.

Authors:  Francis B Ntumngia; Samantha J Barnes; Amy M McHenry; Miriam T George; Jesse Schloegel; John H Adams
Journal:  Clin Vaccine Immunol       Date:  2014-06-25

4.  Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques.

Authors:  A Moreno; I Caro-Aguilar; S S Yazdani; A R Shakri; S Lapp; E Strobert; H McClure; C E Chitnis; M R Galinski
Journal:  Vaccine       Date:  2008-06-23       Impact factor: 3.641

5.  Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.

Authors:  Francis B Ntumngia; Jesse Schloegel; Amy M McHenry; Samantha J Barnes; Miriam T George; Sandra Kennedy; John H Adams
Journal:  Vaccine       Date:  2013-07-31       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.